Panelists emphasize that even after successful surgery, radiation, and adjuvant immunotherapy, vigilant follow-up remains essential. The risk of recurrence or new primary lesions persists, particularly in patients with prior immunosuppression or multiple skin cancers. Routine surveillance visits allow early detection of recurrence and timely management of immune-related side effects that may emerge months after therapy completion.

They recommend structured follow-up schedules combining dermatologic, surgical, and imaging evaluations. Coordination between community dermatologists and oncology centers ensures continuity of care, especially for patients living in remote areas. Digital tracking tools and teledermatology may help improve adherence and monitoring efficiency.

The discussion concludes that long-term management extends beyond disease surveillance to include quality-of-life assessment, functional recovery, and patient education on skin protection. Maintaining multidisciplinary engagement throughout survivorship is critical to achieving durable control and preventing disease recurrence.